Eloralintide 5mg

Eloralintide Peptide

Eloralintide is a synthetic, long-acting peptide designed to activate amylin receptors, with preferential activity at the AMY1 receptor. It is being developed as a novel approach to metabolic disease and obesity research, using the physiological effects of amylin signaling to promote satiety, reduce food intake, and support body-weight reduction.

Eloralintide is also known by the development code LY3841136. Unlike incretin-based agents such as tirzepatide, which activate GIP and GLP-1 receptors, eloralintide works through the amylin signaling pathway. Its molecular design incorporates structural modifications intended to improve stability and extend systemic exposure, including a C20 fatty diacid attached through a linker to a lysine residue. This modification promotes albumin binding and contributes to its prolonged pharmacokinetic profile, supporting once-weekly administration in clinical studies.

---

Overview

Eloralintide represents an emerging approach to weight-management research centered on the amylin receptor system. Amylin is a peptide hormone co-secreted with insulin by pancreatic β-cells and is involved in regulation of appetite, food intake, gastric function, and postprandial metabolic responses.

Preclinical and clinical research suggests that activation of amylin receptors can increase feelings of satiety and reduce caloric intake. Eloralintide was engineered to provide prolonged receptor activity while maintaining a once-weekly dosing profile. Research has particularly focused on its potential to produce substantial reductions in body weight with a different mechanism from GLP-1- and GIP-based therapies.

The molecule is structurally related to amylin-based peptides but incorporates several modifications. Its main polypeptide chain contains 37 amino acids, including non-coded residues, while a modified bridge replaces the native amylin disulfide bond. The peptide is further modified with a C20 fatty diacid side chain to increase albumin binding and prolong exposure.

---

Chemical Makeup

• Molecular Formula: C201H319N49O65S2
• Molecular Weight: 4,526.1 g/mol
• Other Known Titles: LY3298176, GIP/GLP-1 receptor agonist

---

Research Studies and Clinical Trials

Eloralintide and Body Mass Regulation

In a 48-week Phase 2 randomized, placebo-controlled trial, researchers evaluated once-weekly eloralintide in 263 adults with obesity or overweight and at least one weight-related comorbidity. Participants received doses ranging from 1 mg to 9 mg, including dose-escalation regimens.

At Week 48, mean body-weight changes ranged from approximately −9% to −20% across the eloralintide treatment groups, compared with approximately −0.4% with placebo. The 9 mg and 6–9 mg groups each had a reported mean reduction of approximately 20% from baseline. These results were dose-dependent and provided clinical proof of concept for amylin receptor agonism as an approach to weight management.

Impact on Appetite and Energy Intake

Eloralintide’s proposed weight-reduction mechanism differs from that of incretin agonists. Activation of amylin receptors is associated with increased satiety and reduced food intake, providing a physiological signal that can decrease caloric consumption.

Preclinical studies demonstrated dose-dependent reductions in food intake and body weight in both lean and diet-induced-obese animal models. Clinical studies have similarly reported decreased appetite as one of the treatment-emergent effects observed with eloralintide.

This mechanism has generated interest in evaluating eloralintide both as a standalone therapy and in combination with other metabolic agents.

Pharmacokinetics and Long Duration of Action

Eloralintide has been engineered for prolonged systemic exposure. In the Phase 1 clinical study, the median time to maximum plasma concentration was approximately 72–132 hours, while the terminal half-life across the 0.4–12 mg dose range was approximately 310–366 hours, equivalent to roughly 12.9–15.3 days.

The extended pharmacokinetic profile is associated with the molecule’s fatty-acid modification and albumin-binding properties. These characteristics support the investigation of once-weekly subcutaneous administration despite the relatively long terminal half-life.

Safety and Gastrointestinal Tolerability

In the Phase 1 study, eloralintide was generally well tolerated. Reported treatment-emergent adverse events included decreased appetite, headache, fatigue, and gastrointestinal events such as diarrhea, nausea, and vomiting. Most adverse events were mild, and no deaths were reported in the study.

In the larger 48-week Phase 2 trial, nausea and fatigue were among the most frequently reported adverse events, with the frequency of nausea varying across dose groups. These findings demonstrate that gastrointestinal tolerability remains an important area of investigation as development progresses.

Current Clinical Development

Eloralintide has progressed into Phase 3 clinical development. The ENLIGHTEN program is investigating once-weekly eloralintide across several populations, including adults with obesity or overweight without type 2 diabetes, people with obesity or overweight and type 2 diabetes, and people with obesity-associated conditions such as obstructive sleep apnea.

Additional research is examining eloralintide in combination with other metabolic therapies. For example, an ongoing Phase 2 study is evaluating eloralintide together with macupatide, as well as the individual agents, in adults with obesity or overweight without diabetes.

As of 2026, eloralintide remains an investigational drug and has not been established as an approved treatment for obesity or another medical condition.